Invesco LLC Has $2.26 Million Holdings in Abbott Laboratories (NYSE:ABT)

Invesco LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 62.1% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 17,018 shares of the healthcare product maker's stock after acquiring an additional 6,518 shares during the period. Abbott Laboratories comprises approximately 0.9% of Invesco LLC's investment portfolio, making the stock its 29th largest holding. Invesco LLC's holdings in Abbott Laboratories were worth $2,257,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. LaFleur & Godfrey LLC lifted its stake in Abbott Laboratories by 23.5% in the fourth quarter. LaFleur & Godfrey LLC now owns 82,443 shares of the healthcare product maker's stock valued at $9,325,000 after acquiring an additional 15,692 shares during the last quarter. Brighton Jones LLC lifted its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Bank Pictet & Cie Europe AG grew its holdings in Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after purchasing an additional 2,774 shares during the period. TCW Group Inc. increased its position in Abbott Laboratories by 1.9% during the fourth quarter. TCW Group Inc. now owns 24,988 shares of the healthcare product maker's stock worth $2,826,000 after buying an additional 454 shares during the last quarter. Finally, Howard Capital Management Inc. raised its stake in Abbott Laboratories by 5.3% in the fourth quarter. Howard Capital Management Inc. now owns 11,601 shares of the healthcare product maker's stock valued at $1,312,000 after buying an additional 589 shares during the period. 75.18% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the sale, the director now owns 34,058 shares in the company, valued at $4,415,960.28. The trade was a 7.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.46% of the company's stock.

Analyst Ratings Changes

ABT has been the topic of a number of research analyst reports. Morgan Stanley increased their price target on Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research note on Thursday, April 17th. The Goldman Sachs Group raised their target price on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Raymond James Financial upped their price target on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a research note on Thursday, April 17th. Bank of America raised their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Finally, Jefferies Financial Group upped their target price on Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $142.61.

Abbott Laboratories Price Performance

NYSE:ABT traded down $0.62 during mid-day trading on Wednesday, reaching $137.46. The stock had a trading volume of 5,505,352 shares, compared to its average volume of 6,115,125. Abbott Laboratories has a 12 month low of $99.71 and a 12 month high of $141.23. The stock has a market capitalization of $239.16 billion, a PE ratio of 17.83, a P/E/G ratio of 2.53 and a beta of 0.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27. The stock has a 50-day simple moving average of $132.54 and a two-hundred day simple moving average of $127.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.02. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a return on equity of 19.01% and a net margin of 31.89%. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a $0.59 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.72%. Abbott Laboratories's dividend payout ratio is currently 30.61%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.